Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations
Abstract Encorafenib is a potent and selective ATP competitive inhibitor of BRAF V600–mutant kinase approved for patients with BRAF‐mutant melanoma and colorectal cancer. Encorafenib is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro and may be susceptible to drug–drug interactions when co‐...
| Huvudupphovsmän: | , , , , |
|---|---|
| Materialtyp: | Artikel |
| Språk: | English |
| Publicerad: |
Wiley
2023-12-01
|
| Serie: | Clinical and Translational Science |
| Länkar: | https://doi.org/10.1111/cts.13662 |